Patents Assigned to Oryzon Genomics, S.A.
-
Publication number: 20210228490Abstract: The present invention relates to a pharmaceutical composition of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, a process for the preparation thereof and its use in the treatment of diseases.Type: ApplicationFiled: May 6, 2019Publication date: July 29, 2021Applicant: Oryzon Genomics, S.A.Inventors: Reto MAURER, Patrick BUSSON, Georg HUMMEL
-
Patent number: 11034991Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.Type: GrantFiled: March 16, 2017Date of Patent: June 15, 2021Assignee: Oryzon Genomics S.A.Inventors: Elena Carceller González, Tamara Maes, Cristina Mascaro Crusat, Alberto Ortega Muñoz
-
Patent number: 11013698Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.Type: GrantFiled: March 13, 2017Date of Patent: May 25, 2021Assignee: Oryzon Genomics S.A.Inventors: Filippo Ciceri, Serena Lunardi, Tamara Maes, Cristina Mascaro Crusat, Inigo Tirapu Fernandez De La Cuesta
-
Patent number: 10780081Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: June 9, 2017Date of Patent: September 22, 2020Assignee: Oryzon Genomics, S.A.Inventors: Tamara Maes, Cristina Mascarò Crusat, David Rotllant Pozo
-
Patent number: 10329256Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: March 5, 2018Date of Patent: June 25, 2019Assignee: Oryzon Genomics, S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 10265279Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).Type: GrantFiled: March 14, 2017Date of Patent: April 23, 2019Assignee: Oryzon Genomics, S.A.Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
-
Patent number: 10233178Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).Type: GrantFiled: June 15, 2017Date of Patent: March 19, 2019Assignee: Oryzon Genomics, S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte Martinez
-
Patent number: 10221125Abstract: The instant invention relates to novel solid forms of the compound of formula (I) or salts thereof as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.Type: GrantFiled: May 2, 2016Date of Patent: March 5, 2019Assignee: Oryzon Genomics, S.A.Inventors: Ralph Diodone, Urs Schwitter, René Trussardi
-
Patent number: 10214477Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: April 26, 2017Date of Patent: February 26, 2019Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 9944601Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: September 21, 2016Date of Patent: April 17, 2018Assignee: ORYZON GENOMICS, S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 9908859Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.Type: GrantFiled: February 20, 2014Date of Patent: March 6, 2018Assignee: Oryzon Genomics, S.A.Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
-
Patent number: 9790196Abstract: The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.Type: GrantFiled: December 4, 2013Date of Patent: October 17, 2017Assignee: ORYZON GENOMICS S.A.Inventors: Jonathan A. Baker, Matthew Collin Thor Fyfe
-
Patent number: 9708309Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).Type: GrantFiled: September 9, 2015Date of Patent: July 18, 2017Assignee: ORYZON GENOMICS, S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte-Martinez
-
Patent number: 9676701Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.Type: GrantFiled: March 6, 2015Date of Patent: June 13, 2017Assignee: ORYZON GENOMICS, S.A.Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Angeles Estiarte-Martinez, Nuria Valls Vidal
-
Patent number: 9670136Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: September 1, 2016Date of Patent: June 6, 2017Assignee: ORYZON GENOMICS S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 9616058Abstract: The present invention relates to the use of potent selective LSD inhibitors and LSD/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency.Type: GrantFiled: February 24, 2011Date of Patent: April 11, 2017Assignee: Oryzon Genomics, S.A.Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Muñoz, Nathalie Guibourt, Jonathan Alleman Baker
-
Patent number: 9487512Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: October 22, 2012Date of Patent: November 8, 2016Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 9469597Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.Type: GrantFiled: October 22, 2012Date of Patent: October 18, 2016Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, María de los Ángeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
-
Patent number: 9186337Abstract: The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.Type: GrantFiled: February 24, 2011Date of Patent: November 17, 2015Assignee: Oryzon Genomics S.A.Inventors: Jonathan Alleman Baker, Matthew Colin Thor Fyfe
-
Patent number: 9181198Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).Type: GrantFiled: July 27, 2011Date of Patent: November 10, 2015Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez de la Cuesta, Maria de los Ángeles Estiarte-Martínez